Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$11.83 USD
+0.43 (3.77%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $11.84 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
NMRA 11.83 +0.43(3.77%)
Will NMRA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NMRA
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
Other News for NMRA
RBC Capital Reaffirms Their Buy Rating on Neumora Therapeutics, Inc. (NMRA)
Commit To Purchase Neumora Therapeutics At $10, Earn 66.1% Annualized Using Options
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Neumora Therapeutics to host key opinion leader roundtable to discuss KORAs
Analysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Neumora Therapeutics, Inc. (NMRA)